Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials

Joyce P Samuel, Joshua A Samuels, Lauren E Brooks, Cynthia S Bell, Claudia Pedroza, Donald A Molony, Jon E Tyson, Joyce P Samuel, Joshua A Samuels, Lauren E Brooks, Cynthia S Bell, Claudia Pedroza, Donald A Molony, Jon E Tyson

Abstract

Background: Children are increasingly being diagnosed with primary hypertension. The absence of comparative effectiveness research of antihypertensive medications in children has contributed to considerable differences in prescribing practices among physicians treating children with primary hypertension. Even if parallel-group trials had established a best overall choice for most of these children, the best medication for an individual may differ from the best overall medication.

Methods/design: This project consists of a series of systematically administered n-of-1 trials among older children to verify the need for ongoing antihypertensive treatment and, if so, to identify the preferred single drug therapy from among the three major classes of drugs commonly used for primary hypertension (angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics). We will determine whether one of these is the preferred therapy for the great majority of patients. The "preferred" therapy is the drug which produces normal ambulatory blood pressure, with the greatest reduction in blood pressure without unacceptable side effects. We will recruit 50 patients from the Houston Pediatric and Adolescent Hypertension Program clinic. For each patient, the three drugs will be prescribed in random order and each drug will be taken for 2 weeks. The effectiveness of each therapy will be measured with 24-h ambulatory blood pressure monitoring, and tolerability will be assessed using a side effect questionnaire. Participants will rotate through treatment periods, repeating drugs and adjusting doses until the preferred therapy is identified. In assessing whether one of the medications is most effective for the majority of subjects, the primary outcome will be the percentage of participants for whom each drug is selected as the preferred therapy. We hypothesize that no drug will be selected for the great majority of the subjects, a finding that would support consideration of clinical use of n-of-1 trials. Secondary analyses will explore whether patient characteristics predict which medication will be selected as a preferred drug.

Discussion: This study will help optimize care of participating patients and provide evidence regarding the usefulness of n-of-1 trials in identifying appropriate treatment for children with hypertension and potentially other disorders.

Trial registration: Clinicaltrials.gov NCT02412761 (registered 4/8/2015).

Figures

Fig. 1
Fig. 1
N-of-1 design schema
Fig. 2
Fig. 2
Side effect questionnaire

References

    1. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292(19):2350–6. doi: 10.1001/jama.292.19.2350.
    1. Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlöf B, Devereux RB. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study) Eur J Echocardiogr. 2008;9(6):809–15. doi: 10.1093/ejechocard/jen155.
    1. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45(2):198–202. doi: 10.1161/01.HYP.0000154082.72286.2a.
    1. Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, et al. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension. The LIFE study. Am J Hypertens. 2012;25(10):1101–9. doi: 10.1038/ajh.2012.86.
    1. Turnbull F. Blood Pressure Lowering Treatment Trialists C. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35. doi: 10.1016/S0140-6736(03)14739-3.
    1. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) JAMA. 1991;265(24):3255–64. doi: 10.1001/jama.1991.03460240051027.
    1. Hypertension Detection and Follow-up Program Cooperative Group Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242(23):2562–71. doi: 10.1001/jama.1979.03300230018021.
    1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213(7):1143–52.
    1. Chaturvedi S, Lipszyc DH, Licht C, Craig JC, Parekh R. Pharmacological interventions for hypertension in children. Cochrane Database Syst Rev. 2014;2
    1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76.
    1. Batisky DL. What is the optimal first-line agent in children requiring antihypertensive medication? Curr Hypertens Rep. 2012;14(6):603–7. doi: 10.1007/s11906-012-0302-7.
    1. Yoon EY, Davis MM, Rocchini A, Kershaw D, Freed GL. Medical management of children with primary hypertension by pediatric subspecialists. Pediatr Nephrol. 2009;24(1):147–53. doi: 10.1007/s00467-008-0970-3.
    1. Yoon EY, Cohn L, Rocchini A, Kershaw D, Freed G, Ascione F, et al. Antihypertensive prescribing patterns for adolescents with primary hypertension. Pediatrics. 2012;129(1):e1–8. doi: 10.1542/peds.2011-0877.
    1. Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol. 2005;20(6):791–7. doi: 10.1007/s00467-004-1804-6.
    1. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007;298(10):1209–12. doi: 10.1001/jama.298.10.1209.
    1. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users’ guide to the medical literature. JAMA. 2014;311(4):405–11. doi: 10.1001/jama.2013.285063.
    1. Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA. 2006;296(10):1286–9. doi: 10.1001/jama.296.10.1286.
    1. Duan N, Kravitz RL, Schmid CH. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S21–8. doi: 10.1016/j.jclinepi.2013.04.006.
    1. Kravitz RL DN, the DEcIDE Methods Center N-of-1 Guidance Panel (Duan N, Eslick I,, Gabler NB KH, Kravitz RL, Larson EB, Pace WD, Schmid CH, Sim I, Vohra S). Design and implementation of N-of-1 trials: a user’s guide. Rockville, MD: Agency for Healthcare Research and Quality;2014.
    1. Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med. 2011;8(2):161–73. doi: 10.2217/pme.11.7.
    1. Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients’ preferences matter. BMJ. 2012;345 doi: 10.1136/bmj.e6572.
    1. Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181(6):566–77. doi: 10.1164/rccm.200906-0907OC.
    1. Greenfield S, Kaplan S, Ware JE., Jr Expanding patient involvement in care. Effects on patient outcomes. Ann Intern Med. 1985;102(4):520–8. doi: 10.7326/0003-4819-102-4-520.
    1. Guyatt G, Sackett D, Adachi J, Roberts R, Chong J, Rosenbloom D, et al. A clinician’s guide for conducting randomized trials in individual patients. CMAJ. 1988;139(6):497–503.
    1. Mahon JL, Laupacis A, Hodder RV, McKim DA, Paterson NA, Wood TE, et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest. 1999;115(1):38–48. doi: 10.1378/chest.115.1.38.
    1. Scuffham PA, Nikles J, Mitchell GK, Yelland MJ, Vine N, Poulos CJ, et al. Using N-of-1 trials to improve patient management and save costs. J Gen Intern Med. 2010;25(9):906–13. doi: 10.1007/s11606-010-1352-7.
    1. Yelland MJ, Poulos CJ, Pillans PI, Bashford GM, Nikles CJ, Sturtevant JM, et al. N-of-1 randomized trials to assess the efficacy of gabapentin for chronic neuropathic pain. Pain Med. 2009;10(4):754–61. doi: 10.1111/j.1526-4637.2009.00615.x.
    1. Gabler NB, Duan N, Vohra S, Kravitz RL. N-of-1 trials in the medical literature: a systematic review. Med Care. 2011;49(8):761–8. doi: 10.1097/MLR.0b013e318215d90d.
    1. Senior HE, Mitchell GK, Nikles J, Carmont SA, Schluter PJ, Currow DC, et al. Using aggregated single patient (N-of-1) trials to determine the effectiveness of psychostimulants to reduce fatigue in advanced cancer patients: a rationale and protocol. BMC Palliat Care. 2013;12(1):17. doi: 10.1186/1472-684X-12-17.
    1. Nikles CJ, McKinlay L, Mitchell GK, Carmont SA, Senior HE, Waugh MC, et al. Aggregated n-of-1 trials of central nervous system stimulants versus placebo for paediatric traumatic brain injury--a pilot study. Trials. 2014;15:54. doi: 10.1186/1745-6215-15-54.
    1. Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145(3):353–9. doi: 10.1016/j.jpeds.2004.04.009.
    1. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16(10):795–800. doi: 10.1016/S0895-7061(03)00900-2.
    1. Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;5
    1. Haahr M. 2006. . Accessed: 6 June 2013.
    1. Flynn JT, Daniels SR, Hayman LL, Maahs DM, McCrindle BW, Mitsnefes M, et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension. 2014;63(5):1116–35. doi: 10.1161/HYP.0000000000000007.
    1. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142–61. doi: 10.1161/01.HYP.0000150859.47929.8e.
    1. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol. 1977;12(4):297–303. doi: 10.1007/BF00607430.
    1. Flynn JT, Nahata MC, Mahan JD, Jr, Portman RJ, PATH-2 Investigators Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol. 2006;46(8):905–16. doi: 10.1177/0091270006289844.
    1. Hogg RJ, Delucchi A, Sakihara G, Wells TG, Tenney F, Batisky DL, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol. 2007;22(5):695–701. doi: 10.1007/s00467-006-0399-5.
    1. Alpert BS. Validation of the Welch Allyn Spot Vital Signs blood pressure device according to the ANSI/AAMI SP10: 2002. Accuracy and cost-efficiency successfully combined. Blood Press Monit. 2007;12(5):345–7. doi: 10.1097/MBP.0b013e3282c9abf7.
    1. Gimpel C, Wühl E, Arbeiter K, Drozdz D, Trivelli A, Charbit M, et al. Superior consistency of ambulatory blood pressure monitoring in children: implications for clinical trials. J Hypertens. 2009;27(8):1568–74. doi: 10.1097/HJH.0b013e32832cb2a8.
    1. Barnes VA, Johnson MH, Dekkers JC, Treiber FA. Reproducibility of ambulatory blood pressure measures in African-American adolescents. Ethn Dis. 2002;12(4):S3-101-6.
    1. Krmar RT, Berg UB. Long-term reproducibility of routine ambulatory blood pressure monitoring in stable pediatric renal transplant recipients. Am J Hypertens. 2005;18(11):1408–14. doi: 10.1016/j.amjhyper.2005.05.018.
    1. Lurbe E, Redon J. Reproducibility and validity of ambulatory blood pressure monitoring in children. Am J Hypertens. 2002;15(2 Pt 2):69S–73S. doi: 10.1016/S0895-7061(01)02300-7.
    1. Stergiou GS, Alamara CV, Salgami EV, Vaindirlis IN, Dacou-Voutetakis C, Mountokalakis TD. Reproducibility of home and ambulatory blood pressure in children and adolescents. Blood Press Monit. 2005;10(3):143–7. doi: 10.1097/00126097-200506000-00005.
    1. Agarwal R, Weir MR. Treated hypertension and the white coat phenomenon: office readings are inadequate measures of efficacy. J Am Soc Hypertens. 2013;7(3):236–43. doi: 10.1016/j.jash.2013.02.005.
    1. Gorostidi M, Sarafidis PA, de la Sierra A, Segura J, de la Cruz JJ, Banegas JR, et al. Differences between office and 24-h blood pressure control in hypertensive patients with CKD: a 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis. 2013;62(2):285–94. doi: 10.1053/j.ajkd.2013.03.025.
    1. Parati G, Ravogli A, Mutti E, Santucciu C, Omboni S, Mancia G. Ambulatory blood pressure monitoring in the evaluation of antihypertensive drugs. J Hypertens Suppl. 1994;12(8):S9–15.
    1. Neutel JM, Smith DH, Ram CV, Kaplan NM, Papademetriou V, Fagan TC, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med. 1993;94(2):181–7. doi: 10.1016/0002-9343(93)90181-N.
    1. Neutel JM, Smith DH, Ram CV, Lefkowitz MP, Kazempour MK, Weber MA. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. Am J Cardiol. 1993;72(1):41–6. doi: 10.1016/0002-9149(93)90216-Y.
    1. Mansoor GA. Ambulatory blood pressure monitoring in clinical trials in adults and children. Am J Hypertens. 2002;15(2 Pt 2):38S–42S. doi: 10.1016/S0895-7061(01)02295-6.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. doi: 10.1016/j.jbi.2008.08.010.
    1. Punja S, Eslick I, Duan N, Panel tDMCN-o-G. An Ethical Framework for N-of-1 Trials: Clinical Care, Quality Improvement, or Human Subjects Resarch? Rockville, MD: Agency for Healthcare Research and Quality; 2014. Contract No.: Chapter 2.
    1. Faden RR, Kass NE, Goodman SN, Pronovost P, Tunis S, Beauchamp TL. An ethics framework for a learning health care system: a departure from traditional research ethics and clinical ethics. The Hastings Center report. 2013;Spec No:S16-27. doi:10.1002/hast.134.
    1. Kass NE, Faden RR, Goodman SN, Pronovost P, Tunis S, Beauchamp TL. The research-treatment distinction: a problematic approach for determining which activities should have ethical oversight. The Hastings Center report. 2013;Spec No:S4-S15. doi:10.1002/hast.133.
    1. Shamseer L, Sampson M, Bukutu C, Schmid CH, Nikles J, Tate R et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration. J Clin Epidemiol. 2015. doi:10.1016/j.jclinepi.2015.05.018.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa